Juno Therapeutics, Inc. (NASDAQ:JUNO) went up to recover about 175.74% since recording its record low price of $17.52. The stock experienced 7.57% jump, arriving at $48.31 on Nov. 1, 2017. During the day, the stock price traveled from $47.21 to $52. This company shares are -19.15% up from its target price of $39.06 and the current market capitalization stands at $5.14B. The recent change has given its price a 14.27% lead over SMA 50 and 0.35% lead over its 52-week high. The stock witnessed 7.12% gains, 66.19% gains and 88.34% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found JUNO’s volatility during a week at 7.06% and during a month it has been found around 4.77%.Juno Therapeutics, Inc. (JUNO) Top Holders
Institutional investors currently hold around $3.36 billion or 73.8% in JUNO stock. Look at its top three institutional owners. Crestline Management, Lp owns $780.63 million in Juno Therapeutics, Inc., which represents roughly 15.19% of the company’s market cap and approximately 23.25% of the institutional ownership. Similar statistics are true for the second largest owner, Baillie Gifford & Co, which owns 10,848,400 shares of the stock are valued at $487.2 million. The third largest holder is Vanguard Group Inc, which currently holds $282.29 million worth of this stock and that ownership represents nearly 5.49% of its market capitalization.
At the end of 06/30/2017 reporting period, 89 institutional holders increased their position in Juno Therapeutics, Inc. (NASDAQ:JUNO) by some 9,302,807 shares, 72 decreased positions by 3,296,381 and 32 held positions by 62,170,110. That puts total institutional holdings at 74,769,298 shares, according to SEC filings. The stock grabbed 36 new institutional investments totaling 6,286,026 shares while 23 institutional investors sold out their entire positions totaling 2,111,211 shares.Juno Therapeutics, Inc. (NASDAQ:JUNO) Insider Trades
Multiple company employees have indulged in significant insider trading. Juno Therapeutics, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that President of R & D Agarwal Sunil has sold 7,285 shares of Juno Therapeutics, Inc. (JUNO) in trading session dated Oct. 02, 2017. These shares are worth $326,077 and were traded at $44.76 each. The SEC filing shows that Cassidy Bernard J performed a sale of 28,000 shares. The General Counsel & Secretary disposed these shares by way of transaction on Sep. 14, 2017. The company’s shares were given away at $44.92 per share worth to an income of some $1,257,760 on account of Cassidy Bernard J.
EVP & Chief Commercial Officer, Azelby Robert, sold 12,850 common shares of Juno Therapeutics, Inc. (JUNO) in the open market. In a transaction dated Sep. 13, 2017, the shares were put up for sale at an average price of $44.95, raking in a sum of $577,608. After this sale, 37,439 common shares of JUNO are directly owned by the insider, with total stake valued at $1,808,678.
In the transaction dated Sep. 07, 2017, the great number of shares disposed came courtesy the Director; Klausner Richard disposed a total of 12,000 shares at an average price of $42.66, amounting to approximately $511,920. The insider now directly owns 776,985 shares worth $37,536,145.Juno Therapeutics, Inc. (JUNO) Analyst Guide
Several analysts have released their opinion on Juno Therapeutics, Inc. (NASDAQ:JUNO), with 6 analysts believing it is a strong buy. Whereas 4 of them predict the stock is a hold. Also, there are 1 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.82 average brokerage recommendation.